News Focus
News Focus
Followers 77
Posts 11422
Boards Moderated 0
Alias Born 04/03/2014

Re: midastouch017 post# 2578

Thursday, 12/24/2020 8:08:19 AM

Thursday, December 24, 2020 8:08:19 AM

Post# of 4172
From the PR - the key is this news.
Can we get this news before year end?
Will it be positive? If not, it will rank.


In reality, this is not a Covid play and no valuation is included in current price but bad news impacts the SP anyways.


In fact, for the severe Covid cases, there are only handful drugs that actually are under trial at late stage - RDHL, CYDY, MRK, HGEN and RLFTF


However, CYDY is ahead of everyone as the enrollment is complete and P3 results expected by last week of Jan

MRK P3 enrollment is going on and RDHL P2/3 enrollment is going on.

“Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News